Skip to content
IPO Vista
GMP— what is the grey market premium?

Hannah Joseph Hospital IPO

Hannah Joseph Hospital Limitedhannahjosephhospital.com

ListedSMEHealth CareBSE SME
Price band
₹67 – ₹70

Face value ₹10.00

Issue size
₹42.00 Cr

100% fresh capital

Lot size
2000 sh
Bidding
22 – 28 Jan

Lists 2 Feb 2026

Grey market
—

No quote recorded

Market data to 30 Oct 2026. Company figures are as filed, sourced 16 Oct 2026. Every figure’s origin is listed under Sources.

IPOVista score

How this issue scores, and why

Every pillar opens to show the raw metric, the curve it was mapped through, the sub-score and its weight. Disagree with the weighting if you like — the arithmetic is all here.

69Strong
IPOVista score 69 out of 100, graded Strong.

IPOVista score

Broadly well-balanced

63% of the scoring model was backed by disclosed data for Hannah Joseph Hospital, giving medium confidence. Weights for anything missing were redistributed rather than scored as zero.

How this score is built
PillarScoreWeight

Below the line: market sentiment. Capped at 8 of 100 points so a hot grey market can tilt a score but never carry one.

Read this before the number

  • SME platform listing

    SME issues trade in larger lot sizes with thinner volumes than mainboard listings, which makes exiting a position harder.

The IPOVista Score is a transparent summary of disclosed fundamentals and issue terms. It is research, not investment advice, and it cannot predict listing performance.

The company

What the business actually does

Founded 2008 · Madurai, Tamil Nadu · 364 employees

Hannah Joseph Hospital runs a single 150-bed multi-specialty hospital on a two-acre campus in Madurai, Tamil Nadu. Mosesjoseph Arunkumar, a neurosurgeon, started it as a sole proprietorship in 2008, and the hospital moved to its present campus in 2020. Of the 150 sanctioned beds, 133 were operational at the date of the prospectus, spread over six floors covering emergency, four ICUs, a general ward, cath-lab recovery and single and deluxe rooms. Core departments are neurosciences, interventional neuro-radiology, cardiac sciences, trauma care, orthopaedics, neuro-radiology and psychiatry; the company added a cath lab and cardiac operation theatres and performs coronary angioplasties and open-heart surgery. The hospital is NABH-accredited and its laboratory holds NABL certification. Manpower was 364 as on 30 November 2025, including 24 full-time consultants.

Revenue is patient billing at one site. In-patient treatment produced Rs 52.09 crore of FY25 revenue against Rs 5.26 crore out-patient, and in-patient work has stayed near two-thirds of revenue from operations: 67.19% in FY25 and 65.72% in the six months to 30 September 2025. The prospectus names two government schemes, TNNHIS and CMCHIS, both via MDIndia TPA, as an important source of new patient registrations, so tariffs and payment terms are largely set by payers. Capacity binds the model: 133 of 150 sanctioned beds were operational, and Rs 34.98 crore of the Rs 42 crore raised, 83.29% of gross proceeds, was earmarked for a new radiation oncology centre.

The company on paper

Legal name
Hannah Joseph Hospital Limited
IncorporatedThe legal entity is often incorporated years before the brand you know, and may have traded under another name first
24 Oct 2011trading as Hannah Joseph Hospital since 2008
CINCorporate Identity Number — the unambiguous handle for looking this company up at the MCA
U74999TN2011PLC082860
Sector
Health Care · Multi-specialty hospital specialising in neurosciences, cardiac sciences and trauma care
Employees
364
Registered office
Madurai, Tamil Nadu
Promoters
Mosesjoseph Arunkumar, Fenn Kavitha Fenn Arunkumar, Arunkumar Nalina, Noyel Arunkumar
Promoter holding, pre-issue
93.6%
Promoter holding, post-issue
68.8%

The numbers

Financial performance

Revenue has compounded at 19.1% a year across the 3 reported financial years.

Revenue and profit

Figures in ₹ crore, as reported in the prospectus. Interim quarters are not annualised.

  • Revenue
  • Profit after tax

Margin trend

Profit and operating margin as a percentage of revenue

  • Net margin
  • EBITDA margin

Net worth and borrowings

At each period end, in ₹ crore. Gearing below each period is borrowings over net worth, from these same figures.

  • Net worth
  • Total borrowings

The price

Valuation

What the issue asks for the business, set against what the business earns.

No valuation ratios are recorded for this issue. The price band and the reported financials above are what this record holds.

The terms

How the issue is structured

100% of the money raised is fresh capital that goes to the company; the rest goes to shareholders selling down.

Fresh issueNew shares — proceeds go to the company
₹42.00 Cr
Offer for saleExisting shares — proceeds go to the selling shareholders
₹0
Total issue size
₹42.00 Cr
Shares offered in the OFS
—
Pre-issue shares outstanding
—
Employee discount
—
Market maker portionSME issues require a market maker to provide two-way quotes
3,00,000

What the issue does to ownership

Share of paid-up equity before and after the offer. The promoters give up 24.7% of the company.

  • Promoters
  • Everyone else
Before94%After69%31%

Hover or focus a segment to see who it is. The two bars are the same company, measured before and after the offer.

Percentages are of paid-up equity, and the “after” column assumes the offer is fully subscribed, which is how the offer document states it. This record does not disclose a pre- and post-issue share count, so the part of the company actually changing hands is not split out — everyone who is not a promoter is shown together.

Demand

What the market is bidding

Subscription is hard exchange data. Grey-market premium is not — it is an unofficial quote, shown because readers want it and labelled because it deserves the label.

Subscription by category

Cumulative bid multiples at the end of day 4. Anchor allocations are excluded.

QIB1.08×NII / HNI2.34×Retail1.62×

Hover or focus a category to see who bids in it.

Total subscription1.62×

A category subscribed above 1× is oversubscribed; allotment in that category then runs as a lottery or on a proportionate basis.

Grey market premium

Unofficial over-the-counter sentiment

No grey-market quotes have been recorded for this issue.

Outcome

How it actually listed

Issue price
₹70.00
Listed at
₹65.00
Listing gain
down 7.1%
Since listing
up 69.4%

Trading at ₹110.10 on 30 Oct 2026

Against the issue price
up 57.3%

What an allotment is worth now, before costs

Work it out

What this means for one application

Three calculations, each stating the assumption it rests on.

What one application costs

Shares are applied for in whole lots at the cut-off price. The full amount is blocked in your bank account under ASBA, not debited, until allotment.

Lots
2 lots, 4000 shares, ₹2,80,000 blocked
Shares applied for
4,000
At cut-off price
₹70.00
Amount blocked
₹2,80,000

One lot is 2000 shares at ₹1,40,000. This issue requires a minimum of 2 lots, so the smallest application is ₹2,80,000. That is how the SME board is built rather than a quirk of this issue: the minimum application is set above the ₹2,00,000 that caps a retail bid on the mainboard — two lots rather than one. The smallest bid here still sits in the individual investors’ category, the one the subscription figures call retail, and when that category is oversubscribed the minimum application is allotted by draw of lots — so the odds beside this apply directly.

Odds of getting an allotment

When the retail category is oversubscribed, SEBI requires a lottery for the minimum lot. Every application has the same chance, whatever its size.

~62%

chance of one lot, per application

Retail subscription
1.62×
Applicants per share available
1.6× the retail quota

This is an estimate of a lottery, not a prediction. Actual odds depend on the final basis of allotment, how many applications were at the minimum lot, and rejections for technical reasons. Applying from multiple distinct PANs is the only legitimate way to hold more tickets in that lottery.

What it actually did

This issue has listed, so there is a real number instead of a prediction. The grey-market premium is shown beside it for comparison.

₹65.00

listed at, −7.1% against the issue price

Issue price
₹70.00
Premium said
—
If allotted 2000 shares
−₹10,000

Listing-day figures are as reported by the exchanges.

Our read

Easy to misread

Grounded only in figures disclosed in the prospectus. This is analysis, not a recommendation.

Easy to miss in the prospectus

  • The prospectus's own in-patient/out-patient revenue breakup does not sum to revenue from operations. For FY25 it shows in-patient Rs 52.09 Cr plus out-patient Rs 5.26 Cr and labels the Rs 57.36 Cr subtotal "Total" in the business chapter, while the same table reproduced in the risk factors labels the Rs 77.53 Cr line "Total Revenue from Operations". The roughly Rs 20 Cr difference is other operating revenue (pharmacy, diagnostics and similar) that the prospectus does not break out.
  • PAT rose about 7x from Rs 1.01 Cr (FY23) to Rs 7.21 Cr (FY25) while EBITDA rose only from Rs 16.38 Cr to Rs 20.52 Cr, so the profit series is driven by items below EBITDA rather than by margin expansion. Total borrowings fell from Rs 42.95 Cr to Rs 33.58 Cr over the same period.
  • Revenue figures here are restated revenue from operations. Total income, which several trackers print as "revenue", is slightly higher: Rs 54.90 Cr (FY23), Rs 63.63 Cr (FY24) and Rs 77.90 Cr (FY25).

Straight from the filing

Read it yourself

Every figure on this page comes out of these. Go and check them.

Served by the issuer, the exchange or the regulator — never a copy hosted here, so what you open is the filing itself.

The paperwork

Who is running the issue

Lead managers
CapitalSquare Advisors Private Limited
RegistrarAllotment status is checked on the registrar's own site
Bigshare Services Private Limited

How these figures were checked

Reconciled to Hannah Joseph Hospital's own prospectus and to exchange disclosures, then cross-checked against 5 other independently published compilations of the same filing. Where a stated ratio disagreed with the line items it should come from, the disagreement was settled against the prospectus itself.

The prospectus is the authoritative document. Check anything that matters against it before you act.

Other issues worth reading next

KRM Ayurveda

Ayurvedic hospitals and clinics plus branded herbal formulations

Listed 29 Jan 2026 · SME

Price band
₹128 – ₹135
Listing gain
up 27.5%
Score
64/100

Accretion Nutraveda

Contract development and manufacturing (CDMO) of ayurvedic and nutraceutical formulations

Listed 4 Feb 2026 · SME

Price band
₹122 – ₹129
Listing gain
up 48.1%
Score
74/100

Speciality Medicines

Marketing and distribution of specialty pharmaceutical finished formulations

Listed 30 Mar 2026 · SME

Price band
₹117 – ₹124
Listing gain
unchanged 0.0%
Score
85/100